// App-Quantinova.ai

1035 : The adjuvant PANTHER study: A randomized comparison between dose-dense and tailored epirubicin (E), cyclophosphamide (C) and docetaxel (D) vs. standard dose 5-fluorouracil (F), epirubicin (E), cyclophosphamide (C) and docetaxelHealth-related quality of life during ongoing therapy.

Researchers

Presenter

  • Yvonne Brandberg

Principal Investigators

  • Hemming Johansson

  • Mats Hellstrom

  • Theodoros Foukakis

  • Michael Gnant

  • Gunter von Minckwitz

  • Jonas C. S. Bergh

Medical Centers

  • Karolinska Institutet, Department of Oncology-Pathology (OnkPat), Karolinska University Hospital, Stockholm, Sweden

  • Department of Oncology, Karolinska University Hospital, Stockholm, Sweden

  • Karolinska University hospital, Clinical trial Unit Oncology, Stockholm, Sweden

  • Karolinska Institutet, Stockholm, Sweden

  • Medical University of Vienna, Vienna, Austria

  • German Breast Group (GBG), Neu-Isenbug, Germany

  • Karolinska Institutet, Karolinska University Hospital and SweBCG, Stockholm, Sweden

Locations

  • Germany

  • Sweden

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Adrucil injection

  • Fluorouracil

  • Epirubicin

  • Docetaxel

  • Filgrastim

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • EORTC-BR23

  • ISRCTN39017665

  • NCT00798070

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved